HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nathan N Clumeck Selected Research

Infections

10/2008Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nathan N Clumeck Research Topics

Disease

1Infections
10/2008

Drug/Important Bio-Agent (IBA)

1etravirine (TMC-125)FDA Link
10/2008

Therapy/Procedure

1Therapeutics
10/2008